Clinical trial
A Phase 1/2 Open Label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics, and Anti-tumor Activity of ZN-e4 (KP-673) in Patients With Advanced Non-Small Cell Lung Cancer With Activating Epidermal Growth Factor Receptor (EGFR) Mutations
NCT03446417 is registered in ClinicalTrials.gov with Zeno Pharmaceuticals, Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 1/2 Open Label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics, and Anti-tumor Activity of ZN-e4 (KP-673) in Patients With Advanced Non-Small Cell Lung Cancer With Activating Epidermal Growth Factor Receptor (EGFR) Mutations
- Lead sponsor
- Zeno Pharmaceuticals, Inc.
- Phase
- Phase 1
- Overall status
- Completed
- Start date
- April 20, 2018
- Completion date
- November 15, 2022
- Enrollment
- 34 (actual)
- Sites
- 7
Conditions
As the registry lists them; a condition with its own page is linked.